Form 4: Cognex EVP Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Cognex EVP Sheila DiPalma sold 4,002 shares of common stock for approximately $180,150 through a pre-arranged trading plan.
Summary
- Sheila Marie DiPalma, Executive Vice President of Employee Services at Cognex Corp (CGNX), reported sales of common stock.
- On September 5, 2025, 2,002 shares of common stock were sold at a price of $45.00 per share.
- On September 8, 2025, an additional 2,000 shares of common stock were sold at a price of $45.03 per share.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person.
- Following these sales, DiPalma directly beneficially owns 6,582 shares of Cognex common stock.
- DiPalma also holds various non-qualified stock options and restricted stock units (RSUs) with different exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: This filing reports routine insider stock sales executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to manage their equity holdings. It does not indicate any significant change in company fundamentals or management's outlook, thus the sentiment is neutral.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Minimal impact as these are routine, pre-scheduled insider sales under a 10b5-1 plan, which are generally not indicative of a change in management's confidence in the company's long-term prospects. The volume of shares sold is also relatively small compared to the company's total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 02/21/2018 | Date Exercisable for a Non-Qualified Stock Option with an exercise price of $38.39 |
| 11/01/2018 | Date Exercisable for a Non-Qualified Stock Option with an exercise price of $62.48 |
| 02/19/2020 | Date Exercisable for a Non-Qualified Stock Option with an exercise price of $51.49 |
| 02/18/2021 | Date Exercisable for a Non-Qualified Stock Option with an exercise price of $50.94 |
| 02/22/2023 | Date Exercisable for a Non-Qualified Stock Option with an exercise price of $64.43 |
| 02/21/2024 | Date Exercisable for a Non-Qualified Stock Option with an exercise price of $47.21 and for a Restricted Stock Unit |
| 02/20/2025 | Date Exercisable for a Non-Qualified Stock Option with an exercise price of $39.44 and for a Restricted Stock Unit |
| 09/05/2025 | Transaction Date for sale of 2,002 shares of Common Stock |
| 09/08/2025 | Transaction Date for sale of 2,000 shares of Common Stock |
| 10/30/2025 | Date Exercisable for a Non-Qualified Stock Option with an exercise price of $65.90 |
| 02/18/2026 | Date Exercisable for a Non-Qualified Stock Option with an exercise price of $33.04 and for a Restricted Stock Unit |
| 02/21/2026 | Expiration Date for a Restricted Stock Unit grant of 5,295 shares |
| 02/21/2027 | Expiration Date for a Non-Qualified Stock Option grant of 12,500 shares |
| 02/20/2027 | Expiration Date for a Restricted Stock Unit grant of 10,142 shares |
| 11/01/2027 | Expiration Date for a Non-Qualified Stock Option grant of 64,000 shares |
| 02/18/2028 | Expiration Date for a Restricted Stock Unit grant of 15,134 shares |
| 02/19/2029 | Expiration Date for a Non-Qualified Stock Option grant of 64,000 shares |
| 02/18/2030 | Expiration Date for a Non-Qualified Stock Option grant of 80,000 shares |
| 10/30/2030 | Expiration Date for a Non-Qualified Stock Option grant of 100,000 shares |
| 02/22/2032 | Expiration Date for a Non-Qualified Stock Option grant of 44,823 shares |
| 02/21/2033 | Expiration Date for a Non-Qualified Stock Option grant of 56,466 shares |
| 02/20/2034 | Expiration Date for a Non-Qualified Stock Option grant of 68,541 shares |
| 02/18/2035 | Expiration Date for a Non-Qualified Stock Option grant of 41,460 shares |
Keywords
Cognex, CGNX, Insider Trading, Form 4, Stock Sale, Sheila DiPalma, 10b5-1 Plan, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.